GlassScriptPhysician profile
Katherine A Mann
NPI 1801212709
$3,202.54
in general payments reported to CMS, 2019-2025
32 companies · $1,885 in 2025
The $1,885 reported for 2025 was more than what 93% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $14.89 · 2022: $32.60 · 2023: $53.86 · 2024: $1,216 · 2025: $1,885.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,055 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,055.06 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $524.23 | 2024-2025 | Breztri, Airsupra, Farxiga |
| Pfizer INC. | $417.38 | 2024-2025 | |
| Novo Nordisk INC | $371.90 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Astellas Pharma US INC | $189.16 | 2024 | Veozah |
| Lilly USA, LLC | $170.44 | 2024-2025 | Jardiance, Kisunla, Zepbound |
| Amgen INC. | $146.41 | 2023-2025 | Krystexxa, Otezla, Repatha |
| Abbvie INC. | $140.28 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $119.69 | 2024-2025 | Xifaxan |
| Bayer Healthcare Pharmaceuticals INC. | $117.75 | 2024-2025 | |
| Glaxosmithkline, LLC. | $117.72 | 2024-2025 | Trelegy Ellipta |
| Exact Sciences Corporation | $96.41 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Dexcom, INC. | $90.77 | 2024-2025 | Dexcom G6 Transmitter |
| Lundbeck LLC | $66.39 | 2024-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $66.04 | 2024-2025 | Ninlaro, Fruzaqla |
| Shield Therapeutics INC | $59.30 | 2024 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $55.01 | 2025 | |
| Novartis Pharmaceuticals Corporation | $39.99 | 2025 | |
| Boston Scientific Corporation | $39.31 | 2021-2025 | General - Pain Management |
| Otsuka America Pharmaceutical, INC. | $38.08 | 2025 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $36.67 | 2022-2024 | Eliquis |
| Merck Sharp & Dohme LLC | $36.56 | 2024-2025 | Gardasil 9, Capvaxive, Gardasil |
| Sumitomo Pharma America, INC. | $32.16 | 2024-2025 | Gemtesa |
| Celgene Corporation | $29.07 | 2022-2023 | Zeposia |
| Tersera Therapeutics LLC | $26.70 | 2025 | Quzyttir |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $25.80 | 2025 | Caplyta |
| Octapharma USA, INC. | $24.72 | 2024 | Panzyga |
| Sanofi-Aventis U.S. LLC | $23.75 | 2025 | |
| Inspire Medical Systems, INC. | $23.51 | 2024 | Inspire |
| Biogen, INC. | $21.76 | 2025 | Leqembi |
| Blueprint Medicines Corporation | $20.72 | 2023 | Ayvakit |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $18.82 | 2025 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.04 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katherine Mann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.